Le Lézard
Classified in: Health
Subjects: NPT, LEG, POL

AST Applauds Congressional Leaders for Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act

MOUNT LAUREL, N.J., Dec. 28, 2020 /PRNewswire/ -- After nearly 20 years of tireless advocacy from the transplant stakeholder community and some very committed Congressional leaders, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (Immuno Bill) was passed by Congress and signed into law by President Trump. 

The American Society of Transplantation commends Senators Cassidy, M.D. (R-LA), Durbin (D-IL), and Congressmen Burgess, M.D. (R-TX) and Kind (D-WI) for their steadfast support and commitment over many sessions of Congress to make this passage a reality. 

"The passage of the Immuno Bill is a huge victory for kidney transplant recipients, donors, and their families," stated AST President Dr. Richard Formica.

The AST, representing a majority of medical professionals engaged in solid organ transplantation, has long advocated for removing the 36-month immunosuppressive drug coverage limitation for kidney transplant patients. The Immuno Bill passage has remained a top legislative priority for the Society for nearly two decades. During this time, the AST conducted dozens of targeted Capitol Hill fly-ins, connecting-the-dots between members of Congress, transplant medical professionals, patients, and families that reside and work in their Congressional districts and states. Society leaders have also testified in support of the Immuno Bill before the House Energy & Commerce Committee and conducted comprehensive grassroots activities to drive co-sponsorship and overall support of the legislation. Additionally, the AST partnered on many occasions with members of Congress to host Congressional educational briefings to garner support for the Immuno Bill and hosted a Transplant Patient Summit with Congressional leaders that focused on the need to eliminate kidney patients' 36-month immunosuppressive drug coverage limitation.

"Passage of the Immuno Bill will undoubtedly have a positive impact on kidney transplant recipients and their families. Furthermore, elimination of the 36-month immunosuppressive coverage limitation protects the gift and investment of a donor kidney and saves the U.S. Treasury money by preventing kidney failure, a re-transplant, or a return to dialysis," Dr. Formica added.

The AST thanks the U.S. Congress, transplant and kidney stakeholder communities, as well as the Society's membership for working together and staying committed to seeing this critical patient public policy through to completion.

Media Contact: Shauna O'Brien
Sobrien@myast.org / 609-226-3924

SOURCE American Society of Transplantation

These press releases may also interest you

at 15:30
Today, AmerisourceBergen and Good Neighbor Pharmacy kicked off the final day of ThoughtSpot, Good Neighbor Pharmacy's annual conference and trade show representing its commitment to supporting independent pharmacies as community healthcare...

at 15:00
Research presented at the Alzheimer's Association International Conference® (AAIC®) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms. These studies were among...

at 15:00
Much has been learned about SARS-CoV-2, the virus that causes the novel coronavirus, since the beginning of the COVID-19 pandemic. However, questions remain about the long-term impact of the virus on our bodies and brains. New research reported at...

at 15:00
A significant hurdle in developing therapeutics and care models for Alzheimer's disease that work for people of all ethnic and racial backgrounds is the recruitment and retention of traditionally underrepresented groups in clinical trials. At the...

at 15:00
The National Alliance on Mental Illness (NAMI) and The Steve Fund have established a new partnership to promote programs and services to support the mental health of Black families and other families of color, uniting two organizations with a mutual...

at 15:00
Today at the Alzheimer's Association International Conference© (AAIC© 2021), Eli Lilly and Company presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. In the first, greater amyloid plaque changes following...

News published on 28 december 2020 at 10:37 and distributed by: